generation run 2026-05-08
61 min completedmodel pipeline-v5plan not recordedrun/faed8980…Selection
Verification
- record
- seen / partial
- working
The model's own caveats
- structural_inference
- safety_data_unverified
- sparse_evidence
Reproduce
- inputs
- 24 source keys (listed under Sources)
- plan
- not recorded — template version, prompt hash and git SHA are written from 2026-09 onward
- model
- pipeline-v5
- streams
- none — agent transcripts are persisted from 2026-09 onward
21 searches — query, source, results, what was kept and why
| # | source | query | seen | kept | rationale |
|---|---|---|---|---|---|
| 1 | Crossref via verify_doi | 10.1016/j.scijus.2017.12.004 | 1 | 1 | Relevant to predicted GABA-A binding affinity |
| 2 | OpenAlex | flunitrazolam | 58 | 7 | High citation counts and direct relevance to flunitrazolam pharmacology and class context |
| 3 | PubMed · absence | flunitrazolam overdose fatality death toxicology | 0 | 0 | Documented absence of published fatality case reports |
| 4 | PubMed | PMID 41482166 - Wopken MEA neuronal networks | 1 | 1 | Direct potency comparison data for flunitrazolam vs. canonical benzodiazepines |
| 5 | ClinicalTrials.gov · absence | flunitrazolam | 0 | 0 | No trials exist — documented absence |
| 6 | PubMed · absence | flunitrazolam GABA-A receptor binding affinity | 0 | 0 | No substance-specific binding data found in PubMed |
| 7 | PubChem | flunitrazolam | 1 | 1 | Primary chemical identity verification |
| 8 | PubMed | PMID 30578721 - Moosmann phase I metabolism | 1 | 1 | Key metabolism paper confirming in vitro phase I pathways |
| 9 | PubMed | flunitrazolam pharmacology | 7 | 7 | All directly relevant to flunitrazolam pharmacology, detection, and metabolism |
| 10 | PubMed | PMID 29462316 - oral fluid flunitrazolam | 1 | 1 | Key pharmacokinetic study in oral fluid |
| 11 | UK Government GOV.UK | Circular 006/2021 flunitrazolam MDA control | 1 | 3 | Official UK scheduling documentation |
| 12 | PubMed | benzodiazepine tolerance dependence physical withdrawal GABA mechanism | 5 | 1 | Class-level mechanism for tolerance/dependence applicable to flunitrazolam |
| 13 | WebSearch | flunitrazolam first synthesis history research chemical discovery | 1 | 1 | Historical discovery timeline |
| 14 | Scitegrity Blog | April 2023 global controlled drug legislation flunitrazolam | 1 | 1 | Additional jurisdiction scheduling confirmation |
| 15 | HandWiki | Chemistry:Flunitrazolam | 1 | 2 | Historical discovery and legal status verification |
| 16 | WebSearch DEA Federal Register | flunitrazolam DEA controlled substance US scheduling 2023 2024 | 3 | 0 | Documented that flunitrazolam is NOT explicitly DEA-scheduled federally; subject to analogue act analysis |
| 17 | WebSearch | flunitrazolam melting point physical properties crystalline | 1 | 2 | Physical properties not returned by PubChem API |
| 18 | WebSearch | flunitrazolam half-life elimination pharmacokinetics plasma | 1 | 1 | Pharmacokinetic data for duration context |
| 19 | EUDA | benzodiazepines notifications EWS seizures infographic | 1 | 1 | Prevalence data for flunitrazolam in European market |
| 20 | PubChem | CID 137700379 | 1 | 3 | Verification of chemical identity from seed data |
| 21 | PubMed | Pettersson Bergstrand designer benzodiazepine STRIDA 2018 prevalence emergency | 1 | 1 | Real-world clinical intoxication data including flunitrazolam |
74 claims by section — every cited sentence, checked against its source
safety22 · 12 ok
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Sweden (STRIDA project): Detected as a co-intoxicant in 5 of 11 acrylfentanyl intoxication cases. Clinical presentation included decreased consciousness and respiratory depression, though the independent contribution of flunitrazolam could not be delineated from co-ingested fentanyl analogues. Separate STRIDA analyses confirmed flunitrazolam detection in NPS benzodiazepine intoxication presentations.supported
STRIDA project: flunitrazolam detected as co-intoxicant in 5 of 11 acrylfentanyl cases. Demonstrates polydrug use context. 15563650.2017.1303141
Sweden (STRIDA project): Detected as a co-intoxicant in 5 of 11 acrylfentanyl intoxication cases. Clinical presentation included decreased consciousness and respiratory depression, though the independent contribution of flunitrazolam could not be delineated from co-ingested fentanyl analogues. Separate STRIDA analyses confirmed flunitrazolam detection in NPS benzodiazepine intoxication presentations.supported
Bioanalytical and clinical data from NPS BZD intoxications in the Swedish STRIDA project. 15563650.2018.1506130
Sweden (routine toxicology): Detected in patient urine samples from both routine drug testing and acute intoxication emergency ward admissions.supported
Flunitrazolam among 16 detected in patient samples from emergency wards. LOQ 5-50 ng/mL. j.clinms.2018.08.004
Claim in safety — inconclusiveinconclusiveworking →
The compound has been identified as a co-intoxicant in polydrug fatality investigationspartially supported
STRIDA project: flunitrazolam detected as co-intoxicant in 5 of 11 acrylfentanyl cases. Demonstrates polydrug use context. 15563650.2017.1303141
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Drug-facilitated sexual assault (DFSA): Designer benzodiazepines with pharmacological profiles similar to flunitrazolam have been detected in DFSA casessupported
Review of DBZDs in DFSA; discusses pharmacokinetics, short half-life, rapid metabolism, challenges for detection. bkac017
The following account is inferred from the well-characterized class pharmacology of benzodiazepines.supported
BZDs as GABA-A PAMs; prolonged use causes tolerance via GABA-A subunit downregulation and compensatory glutamatergic sensitization. ijms27031430
Claim in safety — inconclusiveinconclusiveworking →
Management requires gradual tapering with a long-acting benzodiazepine (typically diazepam or chlordiazepoxide)supported
management requires gradual tapering. ijms27031430
Management requires gradual tapering with a long-acting benzodiazepine (typically diazepam or chlordiazepoxide)supported
sedative withdrawal treated by gradual taper. pmid:26339207
No substance-specific drug interaction studies have been published; the following is based on class pharmacology and documented co-intoxication patterns.supported
Review of NPS benzodiazepines market and pharmacology. Notes large differences in PK parameters; combination with opiates leads to respiratory depression and death. dta.2211
Flunitrazolam was identified alongside acrylfentanyl in 5 of 11 STRIDA intoxication casessupported
STRIDA project: flunitrazolam detected as co-intoxicant in 5 of 11 acrylfentanyl cases. 15563650.2017.1303141
Claim in safety — inconclusiveinconclusiveworking →
Flumazenil is a competitive antagonist at the GABA-A benzodiazepine binding site that can reverse benzodiazepine-induced sedation and respiratory depressionsupported
Systematic review of flumazenil use in BZD-involved overdose; increasing BZD overdose deaths; risk-benefit analysis supports pre-hospital IM flumazenil. bcpt.70007
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Hepatic impairment (relative): Flunitrazolam undergoes hepatic Phase I metabolism and an unusually complex Phase II glucuronidation pathway requiring multiple UGT enzymessupported
Flunitrazolam glucuronides detected only in pooled human liver microsomes, not individual UGT isoforms, suggesting complex UGT dimer reactions. dta.2463
pharmacology10 · 7 ok
Claim in pharmacology — inconclusiveinconclusiveworking →
Flunitrazolam acts as a positive allosteric modulator (PAM) at the GABA-A receptor, binding to the classical benzodiazepine site located at the interface of α and γ₂ subunits of the pentameric GABA-A receptor complexsupported
BZDs as GABA-A PAMs; prolonged use causes tolerance via GABA-A subunit downregulation. ijms27031430
Claim in pharmacology — inconclusiveinconclusiveworking →
Claim in pharmacology — inconclusiveinconclusiveworking →
The only controlled human pharmacokinetic data derive from a single self-administration study in which a researcher-subject ingested one 0.25 mg oral tablet of confirmed identitysupported
Self-administration study (0.25 mg oral). dta.2480
Oral fluid pharmacokinetics were separately characterized following a controlled single administration.supported
Oral fluid characterization after controlled single 0.25 mg oral administration of flunitrazolam. bky012
Phase I oxidative metabolism (human liver microsomes): Moosmann et al. identified monohydroxylation, dihydroxylation, and reduction of the nitro function as the primary Phase I pathways. The nitro reduction proceeds through an amino intermediate to an acetamide product.supported
Phase I metabolites of flunitrazolam: monohydroxylation, dihydroxylation, and nitro reduction. Structural confirmation by GC-MS, LC-MS/MS, LC-QTOF-MS, and NMR. dta.2561
CYP-dependent formation: In HLM incubations performed by Ameline et al., 7-amino-flunitrazolam was the sole metabolite detected, confirming CYP-dependent nitro reduction as a major pathway. The specific CYP isoforms involved have not been experimentally identified. CYP3A4 is the expected primary oxidative metabolizer based on the pharmacology of structurally related triazolobenzodiazepines (alprazolam, triazolam), but this has not been confirmed for flunitrazolam.supported
HLM incubations: 7-amino-FNTZ only metabolite detected in vitro. dta.2480
Phase II glucuronidation: Pettersson Bergstrand et al. investigated UGT-catalyzed glucuronide conjugation across 13 individual human UGT isoforms. Flunitrazolam glucuronides were detected only in pooled human liver microsomes, not with any individual UGT isoform alone — a pharmacokinetically unusual profile suggesting that glucuronidation requires dimer complexes of multiple UGT enzymes or co-factor interactions absent from single-isoform incubations. By contrast, most other designer benzodiazepines tested (clonazolam, etizolam, flubromazolam) were glucuronidated primarily by UGT1A4. The clinical significance of this anomalous UGT profile is unknown but may contribute to inter-individual variability in elimination.supported
Flunitrazolam glucuronides detected only in pooled human liver microsomes, not individual UGT isoforms, suggesting complex UGT dimer reactions. CYP1A4 catalyzes glucuronidation of related designer BZDs but not flunitrazolam specifically. dta.2463
Elimination: In the Ameline et al. self-administration study (0.25 mg oral), the parent compound was detectable in urine for up to 21 hours post-ingestion at concentrations of 1–18 ng/mL, with approximately 3% of the dose excreted unchangedsupported
Urine detection window: 21h parent, 37h with metabolites. ~3% excreted unchanged. dta.2480
summary9 · 7 ok
Claim in summary — inconclusiveinconclusiveworking →
In vitro functional assays place its potency approximately 10-fold above diazepam and lorazepam, making it among the most potent benzodiazepines — designer or clinical — characterized to date.supported
Flunitrazolam LOEC 0.01 µM on rat cortical MEAs — 10x more potent than diazepam and lorazepam (0.1 µM each). Most potent designer BZD tested. j.neuro.2025.103379
The published evidence base is confined to in vitro metabolism studies, a single controlled self-administration pharmacokinetic study at 0.25 mg, forensic detection method development, and clinical intoxication case series from the Swedish STRIDA projectsupported
Self-administration study (0.25 mg oral). Urine detection window: 21h parent, 37h with metabolites. HLM incubations: 7-amino-FNTZ only metabolite detected in vitro. dta.2480
The published evidence base is confined to in vitro metabolism studies, a single controlled self-administration pharmacokinetic study at 0.25 mg, forensic detection method development, and clinical intoxication case series from the Swedish STRIDA projectsupported
Bioanalytical and clinical data from NPS BZD intoxications in the Swedish STRIDA project. 15563650.2018.1506130
Claim in summary — inconclusiveinconclusiveworking →
Flunitrazolam acts as a positive allosteric modulator at the GABA-A receptor, enhancing chloride conductance in the presence of GABAsupported
BZDs as GABA-A PAMs; prolonged use causes tolerance via GABA-A subunit downregulation and compensatory glutamatergic sensitization. ijms27031430
No substance-specific Ki or EC50 values have been published; potency is inferred from in vitro neuronal network inhibition (lowest observed effect concentration 0.01 µM) and from its structural relationship to flunitrazepamsupported
Flunitrazolam LOEC 0.01 µM on rat cortical MEAs — 10x more potent than diazepam and lorazepam (0.1 µM each). j.neuro.2025.103379
No LD50, therapeutic index, or controlled human toxicity data exist for flunitrazolam. Respiratory depression is the primary acute lethal risk, amplified by co-ingestion of opioids or alcohol — a pattern documented in Swedish intoxication cases where flunitrazolam appeared alongside acrylfentanylsupported
STRIDA project: flunitrazolam detected as co-intoxicant in 5 of 11 acrylfentanyl cases. 15563650.2017.1303141
Tolerance develops within days of continuous use, with full cross-tolerance to all benzodiazepines; abrupt cessation after dependence risks seizuressupported
BZDs as GABA-A PAMs; prolonged use causes tolerance via GABA-A subunit downregulation and compensatory glutamatergic sensitization; management requires gradual tapering. ijms27031430
pharmacokinetic-detail8 · 7 ok
The sole controlled human pharmacokinetic study is the Ameline et al. self-administration experiment, in which one researcher-subject ingested a single 0.25 mg oral tablet whose identity was confirmed by NMRsupported
Self-administration study (0.25 mg oral). dta.2480
In separate HLM incubations performed by Ameline et al., 7-amino-flunitrazolam was the sole metabolite detected, confirming the CYP-dependence of the nitro reduction pathwaysupported
HLM incubations: 7-amino-FNTZ only metabolite detected in vitro. dta.2480
Oral fluid pharmacokinetics following a controlled single administration were separately reported, confirming rapid absorption and oral fluid detectability but not providing full plasma PK characterization.supported
Oral fluid characterization after controlled single 0.25 mg oral administration of flunitrazolam. bky012
Moosmann et al. characterized Phase I metabolic pathways using human liver microsome (HLM) incubationssupported
Phase I metabolites of flunitrazolam: monohydroxylation, dihydroxylation, and nitro reduction. dta.2561
Pettersson Bergstrand et al. investigated glucuronidation of flunitrazolam across 13 individual recombinant human UGT isoformssupported
Flunitrazolam glucuronides detected only in pooled human liver microsomes, not individual UGT isoforms, suggesting complex UGT dimer reactions. dta.2463
Standard benzodiazepine immunoassay panels may cross-react with flunitrazolam but cannot be relied upon for positive identificationsupported
70% of immunoassay-positive but conventional BZD confirmation-negative samples contained at least one designer BZD. bkab013
Claim in pharmacokinetic-detail — inconclusiveinconclusiveworking →
LC-MS/MS confirmation is required for definitive identification in both clinical and forensic contextssupported
Method for 28 NPS BZDs in urine. Flunitrazolam among 16 detected in patient samples from emergency wards. LOQ 5-50 ng/mL. j.clinms.2018.08.004
history6 · 3 ok
In five of eleven STRIDA acrylfentanyl intoxication cases, flunitrazolam was identified as a co-intoxicant.supported
flunitrazolam detected as co-intoxicant in 5 of 11 acrylfentanyl cases. 15563650.2017.1303141
Claim in history — inconclusiveinconclusiveworking →
Claim in history — inconclusiveinconclusiveworking →
Claim in history — inconclusiveinconclusiveworking →
By 2016–2017, the compound was detected in Swedish clinical intoxication cases via the STRIDA project, a national system for monitoring NPS-related poisoningssupported
STRIDA project: flunitrazolam detected as co-intoxicant in 5 of 11 acrylfentanyl cases. 15563650.2017.1303141
By 2016–2017, the compound was detected in Swedish clinical intoxication cases via the STRIDA project, a national system for monitoring NPS-related poisoningssupported
Bioanalytical and clinical data from NPS BZD intoxications in the Swedish STRIDA project. 15563650.2018.1506130
neuroscience5 · 4 ok
The following mechanistic account is inferred from the established neuroscience of benzodiazepine-class GABA-A positive allosteric modulation.supported
BZDs as GABA-A PAMs; prolonged use causes tolerance via GABA-A subunit downregulation and compensatory glutamatergic sensitization. ijms27031430
The following mechanistic account is inferred from the established neuroscience of benzodiazepine-class GABA-A positive allosteric modulation.supported
Review of NPS benzodiazepines market and pharmacology. dta.2211
The in vitro demonstration that flunitrazolam inhibits spontaneous cortical network activity at 0.01 µM directly recapitulates this mechanism at the cellular level.supported
Flunitrazolam LOEC 0.01 µM on rat cortical MEAs. Dose-dependent decrease in neuronal activity with increased burst duration. j.neuro.2025.103379
Claim in neuroscience — inconclusiveinconclusiveworking →
Dose-response in human cortical networks: The in vitro LOEC of 0.01 µM was established in rat cortical cultures. How this translates to human cortical network dynamics — particularly regional selectivity, temporal dynamics, and dose-response slope — is unexplored.supported
Flunitrazolam LOEC 0.01 µM on rat cortical MEAs — 10x more potent than diazepam and lorazepam (0.1 µM each). Most potent designer BZD tested. j.neuro.2025.103379
chemistry4 · 1 ok
Claim in chemistry — inconclusiveinconclusiveworking →
Claim in chemistry — inconclusiveinconclusiveworking →
The structural formula was independently confirmed by GC-MS, LC-MS/MS, LC-QTOF-MS, and NMR spectroscopy, matching the identity declared by research chemical vendors.supported
Structural confirmation by GC-MS, LC-MS/MS, LC-QTOF-MS, and NMR. dta.2561
Claim in chemistry — inconclusiveinconclusiveworking →
comparative-pharmacology4 · 1 ok
Claim in comparative-pharmacology — inconclusiveinconclusiveworking →
Wopken et al. measured the lowest observed effect concentration (LOEC) for inhibition of spontaneous activity in primary rat cortical neuronal networks:supported
Flunitrazolam LOEC 0.01 µM on rat cortical MEAs. Dose-dependent decrease in neuronal activity with increased burst duration. j.neuro.2025.103379
Claim in comparative-pharmacology — inconclusiveinconclusiveworking →
Claim in comparative-pharmacology — inconclusiveinconclusiveworking →
clinical-evidence3 · 3 ok
The only published human exposure data come from controlled self-administration pharmacokinetic studies (n = 1) designed to characterize metabolite profiles and detection windows for forensic purposessupported
Self-administration study (0.25 mg oral). Urine detection window: 21h parent, 37h with metabolites. Metabolites: desnitro-FNTZ, 7-acetamido-FNTZ, 7-amino-FNTZ. dta.2480
The only published human exposure data come from controlled self-administration pharmacokinetic studies (n = 1) designed to characterize metabolite profiles and detection windows for forensic purposessupported
Oral fluid characterization after controlled single 0.25 mg oral administration of flunitrazolam. bky012
Clinical intoxication data from the Swedish STRIDA project document real-world adverse presentations but are observational, uncontrolled, and frequently complicated by polydrug exposure.supported
STRIDA project: flunitrazolam detected as co-intoxicant in 5 of 11 acrylfentanyl cases. Demonstrates polydrug use context. 15563650.2017.1303141
receptor-pharmacology3 · 3 ok
Waters et al. developed a quantitative structure-activity relationship (QSAR) model to predict GABA-A receptor binding affinity for novel benzodiazepines, including flunitrazolamsupported
QSAR model for predicting GABA-A receptor binding of novel benzodiazepines including flunitrazolam. j.scijus.2017.12.004
The most informative potency data come from Wopken et al., who measured the effects of benzodiazepines — both clinical and designer — on spontaneous activity of primary rat cortical neuronal networks using microelectrode arrays (MEAs)supported
Flunitrazolam LOEC 0.01 µM on rat cortical MEAs. Dose-dependent decrease in neuronal activity with increased burst duration. j.neuro.2025.103379
Flunitrazolam produced the lowest observed effect concentration of all benzodiazepines tested — canonical or designer — at 0.01 µM, 10-fold below diazepam and lorazepam and 100-fold below oxazepampartially supported
Flunitrazolam LOEC 0.01 µM on rat cortical MEAs — 10x more potent than diazepam and lorazepam (0.1 µM each). Most potent designer BZD tested. j.neuro.2025.103379